Funding for this research was provided by:
Received: 29 March 2022
Accepted: 3 May 2022
First Online: 24 May 2022
: The Capital Region of Denmark Ethical Committee approved the study (H-2–2012-016) as part of a sleep CH-study [CitationRef removed]. After this study was completed the survey did not need further formal approval from the ethics committee (file-number: 17008910). Patients gave informed oral and written consent according to the Helsinki declaration.
: Not applicable.
: ASP: Current sub-investigator in trial for Lundbeck. Previous sub-investigator in trials for Eli-Lilly, and CCH pharmaceuticals. NL reports no disclosures. AS: Previous sub-investigator in trial for Lundbeck. AS was working as a MD in the Danish Headache Center at time of drafting the paper but is currently employed by Lundbeck Pharma (since 1.FEB.2022). She approved the manuscript but has not made any changes since working at Lundbeck Pharma. Previous sub-investigator in trial for Eli-Lilly. RHJ: Lectures for Pfizer, Eli-Lilly, Merck, TEVA, Novartis, Lundbeck and Allergan. Investigator in clinical trials with Eli-Lilly, Novartis and Lundbeck. MB reports no disclosures.The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.